Thornton & Ross News

Leading pharmaceutical company invests in seven-figure state-of-the-art facility

Huddersfield, October 9, 2019 – Huddersfield pharmaceutical company Thornton & Ross is expanding, with a new seven-figure state-of-the-art facility due to open at the beginning of January.

The technologically advanced 600 sqm bottling and filling line will be incorporated within the existing Thornton & Ross warehouse, in order to preserve the highest standards of hygiene.

The move is part of ambitious growth plans by Thornton & Ross – Huddersfield’s largest employer – and represents the most significant investments Thornton & Ross parent company, STADA, has made in the UK. Forty permanent jobs will be created at the site.

The process design and engineering work will be implemented by Haden Freeman, a process engineering consultancy headquartered in Denton.

Following a recommendation, Haden Freeman conducted an initial site visit and carried out checks for potential hazards before drawing up a detailed strategy for the new facility. A project manager was appointed along with site and office teams to ensure all work complied with Haden Freeman’s ISO:9001 2015 certified quality standards.

The building and civil engineering works will be completed by Hawkins Construction (Northern) Ltd, which is a well-established construction company specialising in this type of installation within a hygienic environment.

Hawkins Construction (Northern) Limited aims to deliver the new facility with minimal impact and without significant downtime on existing filling lines. Hawkins Construction and Haden Freeman already have an excellent working relationship, having recently worked together on number of challenging but successful projects within the manufacturing sector.

The scheme is expected to take 22 weeks to complete, with a completion date of January 1st 2020. Work will involve demolition and alterations to structures around existing production lines, structural steelwork and gantries, internal hygiene standard fire walls, walk on ceiling, Electrical & Mechanical design and installation, hygiene doors, stainless steel kerbs and specialist anti-dissipative hygienic flooring.

Mark Kirkup, Thornton & Ross Vice-President of UK Operations, said the new facility was essential in enabling the company to expand: “This facility represents the largest single investment that our parent company, the STADA Group, has made at our UK site and underlines the success of Thornton & Ross as a company.

“It will form an integral part of our plans to expand, which include the creation of 40 new permanent positions across the company.

“We selected our partners on this project for their technical capabilities and experience of working in similar environments. Despite the short timeframe for completion, we are extremely pleased with how the project is progressing and look forward to seeing the new bottling line in action.”

Shaun Sykes, Managing Director at Hawkins Construction, added: “Hawkins Construction are extremely proud to be involved with this project and look forward to working closely with Thornton & Ross and building our relationship with the project team involved. Our teams will ensure all work complies with our ISO:9001 2015 certified quality standards.”

Thornton & Ross develops, manufactures and supplies a wide range of branded over-the-counter medicines, dermatological solutions and other healthcare and hygiene products including Zoflora®, Hedrin® and Setlers®. It is part of the German-based STADA Group.

New Facilities Team 2019 New Facilities Team 2019
At the site of the new bottling facility are, from left: Paul Ward, project manager, Thornton & Ross; Roger Scarlett-Smith, Vice-President of UK Operations, Thornton & Ross; Shaun Sykes, Managing Director, Hawkins Construction; and Robert Warlow, Project Manager, Haden Freeman.


STADA to Become a Major Pharma Player in Ukraine by Acquiring Biopharma's Pharmaceutical Prescription and Consumer Health Business

The STADA Group continues its growth trajectory in Europe. The company, announced that it is acquiring the pharmaceutical business of Biopharma, one of the key pharmaceutical producers in Ukraine.

Click for more info

Is veganism good for your health?

The Future of Your Health report indicates that nearly a third of Brits don’t think so

Click for more info


Biopharmaceutical company Alvotech and global pharmaceutical company STADA Arzneimittel AG ("STADA") today announced that they have entered into an exclusive strategic partnership for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe.

Click for more info

STADA invests $660 Million USD in Takeda's OTC portfolio in Russia/CIS to become a major player in these branded markets

STADA to acquire a portfolio of approximately 20 selected OTC and prescription pharmaceutical products in Russia, Georgia and CIS countries

Click for more info

STADA to acquire Walmark - a leading Consumer Healthcare company in Central Europe

STADA Arzneimittel AG ('STADA' or 'the Group') today announces the acquisition of Walmark a.s. ('Walmark' or 'the company') from Mid Europa Partners for an undisclosed consideration.

Click for more info

Q&A 2019 Pharmacy Show

A Q&A Session with Phoebe Buckley on the 2019 Pharmacy Show

Click for more info

STADA Health Report 2019

More than half of people in UK are optimistic about the future of health

Click for more info

Leading pharmaceutical company invests in seven-figure state-of-the-art facility

Huddersfield pharmaceutical company Thornton & Ross is expanding, with a new seven-figure state-of-the-art facility due to open at the beginning of January.

Click for more info

>> News Archive